Mental health experts question whether allowing Johnson & Johnson to market its antipsychotic med Invega Sustenna as a way to prevent arrest is really a good idea.
J&J's new meds came on strong again in Q2, helping fuel a 9% increase in pharma sales--good news for the healthcare giant as Remicade biosimilars wait in the wings.